Bone's Allob meets in Phase I/IIa for delayed-union bone fractures

In September, Bone Therapeutics S.A. (Euronext:BOTHE) reported interim data from a Phase I/IIa trial in 16 patients with delayed-union fractures of long bones showing that Allob met the primary endpoint of improving radiological Tomographic Union Score (TUS) by ≥2 points or of improving clinical Global Disease Evaluation (GDE) by ≥25% from baseline to 6 months. Specifically, all 16 patients achieved the endpoint. Bone stopped the trial early following a recommendation from the trial’s DSMB.

Additionally, Allob led to a mean increase of 4 points in TUS score, with 13 patients achieving a ≥2-point increase, and a mean increase of 48% in GDE score, with 12 patients achieving a ≥25% improvement. Allob also met the secondary endpoint of reducing pain at the fracture site at 6 months compared to baseline (59% reduction). Allob was well tolerated...